Urogen Pharma LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Monograph Capital Exits Significant Stake in UroGen Pharma, Files Final Beneficial Ownership Amendment
Monograph Capital Partners I, L.P. and its affiliated reporting persons have filed an exit amendment to their Schedule 13D, indicating they no longer beneficially own more than 5% of UroGen Pharma Ltd.'s Ordinary Shares after selling 733,712 shares.